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Abstract
Introduction: Cardiac biomarkers may be invaluable in establishing the diagnosis of acute myocardial infarction
(AMI) in the ED setting.
Objective: To assess the diagnostic indices of the Cardio Detect assay and the quantitative cardiac troponin T test,
in diagnosing AMI in the ED, according to the time of onset of chest pain.
Methodology: A total of 80 eligible patients presenting with ischemic type chest pain with duration of symptoms
within the last 36 h were enrolled. All patients were tested for H-FABP and troponin T at presentation to the ED. A
repeated Cardio Detect test was performed 1 h after the initial negative result, and a repeated troponin T test was
also performed 8-12 h after an initial negative result. The diagnostic indices [sensitivity, specificity, positive
predictive value, negative predictive value, receiver operating curve (ROC)] were analyzed for Cardio Detect and
Troponin T (individually and in combination) and also for the repeat Cardio Detect test. Data entry and analysis
were performed using SPSS version 12.0 and Analyze-it software.
Results: The Cardio Detect test was more sensitive and had a higher NPV than the troponin T (TnT) test during
the first 12 h of onset of chest pain. The repeat Cardio Detect had better sensitivity and NPV than the initial Cardio
Detect. The sensitivity and NPV of the combination test (Cardio Detect and troponin T) were also superior to each
test performed individually.
Conclusion: The Cardio Detect test is more sensitive and has a better NPV than the troponin T test during the first
12 h of AMI. It may be used to rule out myocardial infarction during the early phase of ischemic chest pain.
Background
Early and correct diagnosis of patients admitted to the hos-
pital with symptoms suggestive of acute myocardial infarc-
tion (AMI) is paramount to ensure appropriate therapy is
given to minimize myocardial injury and improve clinical
outcome [1]. The urgency in recognizing and treating
patients with an AMI as early as possible has been repeat-
edly stressed and reiterated in various guidelines that lead
to the well-known phrase of ‘time loss is myocardium loss’.
With the passing of time and further delay in diagnosing
AMI and administration of reperfusion therapy, more
cardiac muscle will be damaged [2]. As a consequence, the
patient’s prognosis will deteriorate. To expedite the diagno-
sis, the AHA (American Heart Association) Guidelines for
the management of patients with ST-elevation myocardial
infarction (STEMI) in 2004 recommended that an electro-
cardiogram (ECG) should be performed and interpreted by
an experienced physician within 10 min of arrival to the
emergency department (ED). If reperfusion therapy is
deemed indicated, the decision whether to use fibrinolytic
therapy or percutaneous coronary intervention (PCI)
should be made within the next 10 min [3,4].
It is equally important to identify patients who are not
suffering from AMI and who can be sent home safely
early after admission. This will avoid unnecessary inpatient
* Correspondence: nhliza@hotmail.com
1School of Medical Sciences, USM, Kubang Kerian, Malaysia
Full list of author information is available at the end of the article
Hisamuddin NAR and Suhailan M International Journal of Emergency Medicine 2011, 4:67
http://www.intjem.com/content/4/1/67
© 2011 Hisamuddin NAR and Suhailan M; licensee Springer. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.hospital admission, which is usually accompanied by
numerous invasive tests. The diagnosis of AMI has to be
accurate and precise. In the unfortunate event that a
patient is mistakenly treated for AMI without having the
condition, unwarranted risk and complications may result
from the reperfusion therapy. This not only poses an
imminent danger to the patient, but also is a potential
source of litigation. Another scenario with potentially cata-
strophic consequences is discharging a patient who is
actually suffering from a myocardial infarct. About 2-8%
of patients who presented with chest pains to the ED were
misdiagnosed and sent home [5]. The morbidity and mor-
tality in these patients were high. Patients could be mis-
diagnosed and inappropriately discharged especially if they
presented with atypical chest pain and non-diagnostic
ECG changes [6].
Therefore, diagnosing an AMI as early and as accu-
rately as possible is the most critical phase in the treat-
ment of a patient presenting with chest pain to the ED.
Once a definitive diagnosis can be made, prompt steps
can be taken to limit the myocardial necrosis, including
instituting reperfusion therapy. The World Health Orga-
nization (WHO) criteria for the definition of AMI
includes a combination of two out of three characteristics
composed of clinical history, a rise and fall of cardiac bio-
markers, and ECG changes. Despite being guided by the
WHO criteria, the diagnosis of AMI may still be challen-
ging in many instances. Patients may present with atypi-
cal symptoms, or myocardial necrosis may occur without
any symptoms at all [7,8]. Not all patients who develop
myocardial necrosis exhibit ECG changes. Approximately
40% of patients with AMI showed no diagnostic ECG
changes on admission. It has been reported that 50% of
the AMI patients who were admitted with acute chest
pain did not have any diagnostic changes on initial ECG
tracing. Therefore, a normal ECG does not rule out the
diagnosis of MI [9-11].
In situation like these, cardiac biomarkers may be
invaluable in establishing a diagnosis of AMI in the ED
setting. A number of established cardiac biomarkers have
been available on the market, and several new promising
assays with better sensitivity have been discovered. In
April 2000, the Joint European Society of Cardiology/
American College of Cardiology Committee (ESC/ACC)
for the Redefinition of Myocardial Infarction published
new criteria for the diagnosis of AMI. They proposed the
use of cardiac troponin (I or T) as the most sensitive and
specific marker of AMI. This revised definition of AMI
has reiterated the importance of cardiac-specific markers
of necrosis, specifically the cardiac troponins, as crucial
determinants for the diagnosis of AMI [12].
A recent potential cardiac biomarker that shows
release kinetics similar to myoglobin is heart-type fatty
acid-binding protein (H-FABP). It is a low-molecular-
weight cytoplasmic protein (15 kDa) that is present in
abundance in the cytosol of cardiac myocytes [13,14]. It
is undetected in normal conditions, but is rapidly
released into the circulation after myocardial cell
damage. Many studies have been conducted on H-
FABP, but few have investigated the diagnostic accuracy
and practicality of Cardio Detect
®. We believe that this
diagnostic kit, which detects H-FABP at the bedside,
still needs further evaluation, especially to assess its per-
formance and practicality to detect AMI in patients pre-
senting with chest pain in the ED setting.
General objectives
The diagnostic indices and clinical utility of qualitative
Cardio Detect
® test kit in the diagnosis of AMI in the
emergency department was evaluated in comparison to
the quantitative cardiac troponin T assay.
Specific objectives
1. To compare the diagnostic indices [sensitivity, specifi-
city, positive predictive value, negative predictive value,
receiver operating characteristic (ROC) curve] of the
qualitative Cardio Detect
® a s s a ya n dt h eq u a n t i t a t i v e
cardiac troponin T test in diagnosing AMI in the ED
according to the time of onset of chest pain.
2. To verify whether there was any improvement in
the diagnostic indices (sensitivity, specificity, positive
predictive value, negative predictive value, ROC) of the
Cardio Detect
® test in diagnosing AMI when repeated 1
h after an initial negative result in patients with acute
ischemic type chest pain presenting to the ED.
3. To determine whether there was any improvement in
the diagnostic indices (sensitivity, specificity, positive pre-
dictive value, negative predictive value, ROC curve) of the
Cardio Detect
® assay in diagnosing AMI when used in
combination with the cardiac troponin T test in patients
with acute ischemic chest pain presenting to the ED.
Methodology
This study was a prospective cross-sectional study. It
was conducted from February 2008 until September
2008, and the source population was all patients who
presented with chest pain suggestive of AMI to a regio-
nal tertiary center with an attendance rate exceeding
70,000 patients per year. Ethical approval was obtained
from the department board review and hospital ethics
committee on 13 February 2008 [reference USMKK/
PPP/JEPeM 199.3(10)]. A short-term grant was
approved by the School of Medical Sciences, USM. The
eligible population was the source population fulfilling
the inclusion and exclusion criteria.
Inclusion criteria
1. Adult patients 18 years old or above.
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chest pain that was less than 36 h duration of onset.
Exclusion criteria
1. Patients with a history of recent muscle injury (<
3 days), including intramuscular injection.
2. Patients with acute or chronic skeletal muscle
damage or disorders including rhabdomyolysis, der-
matomyositis, muscular dystrophy, and polymyositis.
3. Patients with renal insufficiency as defined by
serum creatinine > 200 μmol/l.
4. Critically ill patients, including those with cardio-
genic shock, septic, intubated and ventilated patients.
5. Patients who had had a recent myocardial infarction
or received fibrinolytic therapy or angioplasty within
the last 14 days prior to presentation to the ED.
The sampling method for this study was obtained
through convenience sampling. Patients were enrolled
during all shifts and days of the week. The sample size
was calculated by a biomedical statistician with reference
to ‘Statistical Evaluation of medical tests for classification
and prediction; study design and hypothesis testing’
(Margaret Sullivan Pepe, Oxford University Press 2003).
The variables used in the calculation were as follows:
Type I error is 5% (a = 0.05)
Power of study = 0.8
Eighty-seven patients required, which included a 20%
dropout rate in this study.
Upon arrival at the emergency department (ED), all
patients with chest pain suggestive of myocardial infarc-
tion were triaged. These cases were fast tracked, and seen
by a paramedic or medical officer as soon as possible. An
ECG was performed mostly within 10 min of presentation
to the ED. The ECG was repeated after 1 h of the first
ECG if indicated. After informed consent was obtained, a
blood sample was drawn either through a needle or aspi-
rated via an intravenous cannula; 10 ml of blood was
drawn into a plastic syringe without added heparin. A por-
tion of the blood was tested for both TnT and H-FABP,
irrespective of the ECG findings. The remaining blood
samples were tested for other routine blood investigations,
including full blood count (FBC), renal profile (RP), and
cardiac enzymes (creatine kinase). Presence of H-FABP in
the circulation was detected using the point-of-care Cardio
Detect
® med card. The med card was stored in a desig-
nated refridgerator in the ED Satellite Laboratory. All med
cards were sealed in a plastic pouch and kept between the
temperatures of 2-8°C, as recommended by the manufac-
turer (rennesens GmbH: instructions for use). As the med
card is retrieved, the plastic pouch is opened, and it is
placed horizontally on an even surface (Figures 1 and 2).
The cardiac troponin T (TnT) test was performed using
the Cardiac Reader analyzer (Roche Diagnostics) located
in the satellite laboratory in the ED. It is a qualitative assay
of TnT in heparinized venous blood. A portion of the
blood sample drawn from the patient was inserted into a
heparinized tube provided with the TnT test kit. Regard-
less of patient’s decision to participate in the study or not,
all received routine institutional care. Treatment for AMI
was not withheld. Based on predetermined criteria, the
attending physician (emergency physician or medical phy-
sician) made the final diagnosis, and subjects were classi-
fied into two groups: (1) acute myocardial infarction and
(2) non-acute myocardial infarction. The diagnosis of AMI
is made based on the redefinition of AMI by ESC/ACC
and/or the WHO criteria.
Data entry and analysis were performed with Statistical
Packages for Social Sciences (SPSS version 11.0 for
Windows, Chicago, IL), which were licensed to the
School of Medical Sciences, University Sains Malaysia.
Mean and standard deviation were obtained for all the
numerical variables (age and serum creatinine). Descrip-
tive statistics (frequencies) were obtained for all patients
such as age, gender, comorbidity, and past medical his-
tory. The independent variables were all patients present-
ing with chest pain (categorical) as in the inclusion
criteria, including the timing of onset (numerical) of
chest pain. The dependent variables included the qualita-
tive (positive or negative) outcome of the bedside test for
both test kits. Sensitivity, specificity, PPV, NPV, and ROC
were obtained for the Cardio Detect and TnT (individu-
ally and in combination) and for the repeated Cardio
Detect test. All diagnostic indices were determined for
each test under consideration at the following interval
from the onset of chest pain: (1) 4 h or less (group 1), (2)
more than 4 h but 12 h or less (group 2), (3) more than
12 h but 24 h or less (group 3), and (4) more than 24 h
after onset of chest pain (group 4).
Results
Eighty patients were recruited into the study, of which 62
(77.5%) were male and 18 (22.5%) were female. The
recruitment number was still within the required sampling
of 20% dropout (minimum of 70 patients needed).
Baseline characteristics for the study population are
shown in Table 1. Thirty-two patients (40%) turned up at
the ED within 4 h after onset of chest pain (group 1 = 32
patients). Thirty-one patients (38.8%) presented after 4 h,
but within 12 h of chest pain (group 2 = 31 patients). Thir-
teen (16.3%) subjects came to the ED after 12 h but within
24 h of chest discomfort (group 3 = 13 patients). Only
four patients (5%) presented late to ED after more than
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findings in the ED. The majority of patients (72.5%) in this
study did not have an AMI. Twenty-two patients (27.5%)
were diagnosed with AMI as the final diagnosis made by
the attending physicians. Of the 22 patients diagnosed
with AMI, 14 (63.6%) had non-ST elevation myocardial
infarction (NSTEMI). The remaining eight patients
(36.4%) had ST elevation myocardial infarction (STEMI).
Out of the 32 patients who presented to the ED within 4 h
after the onset of chest pain, 10 (31.2%) had AMI (group
1). Six of the 31 patients (19.3%) who presented after 4 h
but within 12 h of chest pain had AMI (group 2). Five of
the 13 patients (38.4%) had AMI in the group of patients
who turned up after 12 h but within 24 h of chest pain
(group 3). Finally, one of the four (25%) late presenters
who came after 24 h of chest pain had AMI (group 4).
Tables 2, 3, and 4 summarize the diagnostic indices
for Cardio Detect, repeated Cardio Detect, TnT, and
combination tests.
Discussion
Myocardial infarction reflects the cell death of cardiac
myocytes caused by prolonged ischemia, which is the
result of a perfusion imbalance between supply and
demand. It occurs when myocardial ischemia exceeds a
critical threshold and overwhelms myocardial cellular
repair mechanisms that are designed to maintain normal
operating function and homeostasis [15]. If the resultant
ischemia is severe enough to cause sufficient myocardial
damage, detectable quantities of cardiac biomarkers will
be released into the bloodstream [16]. Cardiac biomarkers
have characteristic release and clearance kinetics. Thus,
Figure 1 Flow chart of the study.
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clearance may confound the interpretation of biomarkers
[17]. They are released from necrotizing myocardium in a
time-specific manner. Biochemical markers of myocardial
injury, such as cardiac troponin and creatine kinase (CK),
are detected in plasma approximately 4-6 h after the onset
of myocardial injury, and their plasma level returns to nor-
mal after 7-10 days for cardiac troponin and 50-70 h for
CK [18]. Myoglobin is the earliest biochemical marker of
myocardial cell damage, and it is detectable in blood
within 1 to 2 h of myocardial damage [19].
Serial sampling of multiple cardiac markers beginning
at the time of presentation is currently recommended
[20]. The sensitivity of serial measurements of multiple
markers nears 100%, whereas the sensitivity of a single
measurement of any biomarker at the time of
Figure 2 Visual interpretation of Cardio Detect med card.
Table 1 Baseline characteristics of the study population.
Characteristics Study population AMI No AMI
N 80 22 58
Age (years)
(mean ± SD)
58.96 ± 12.4 59.45 ± 13.9 58.78 ± 11.9
Men/women 62/18 20/2 42/16
Diabetes 22 6 16
Hypertension 43 10 33
Hyperlipidemia 26 6 20
Smoking 38 13 25
Previous history of
CVD
44 9 35
Serum creatinine
(μmol/l ± SD)
115.1 ± 28.5 117.0 ± 27.4 114.4 ± 29.1
Family history of
heart disease
22 5 17
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Page 5 of 9presentation is poor. The recommended time between
the first and second blood draw is 6 to 7 h [21,22]. If
cardiac marker levels are not elevated but clinical suspi-
cion remains high, a third set of markers should be
drawn at 12 to 24 h after presentation [23]. A multimar-
ker approach with different release kinetics to diagnose
AMI was also recommended. H-FABP is a low-molecu-
lar-weight cytoplasmic protein (15 kDa) that is present
in abundance in the cytosol of cardiac myocytes. It plays
an important role in the uptake and oxygenation of
long-chain fatty acids in the heart [24,25]. It is unde-
tected in normal conditions, but is rapidly released into
the circulation after myocardial cell damage. Plasma
level rises as early as 1-3 h after AMI. H-FABP level
peaks at 6-8 h and returns to normal within 24-36 h
after the initial insult [26-29].
The Cardio Detect
® was more sensitive and had a
higher NPV than TnT during the first 12 h of onset of
chest pain. The higher sensitivities of Cardio Detect
® in
the early phase of chest pain were also reported in other
studies [30,31]. The sensitivity of Cardio Detect
® in
group 1 (≤ 4 h) was 50% and in group 2 (> 4 h but ≤ 12
h) was 83.3%, compared with 10% and 71.4% of TnT.
This could be explained by the fact that H-FABP is
released into the circulation as early as 30 min after myo-
cardial necrosis and reaches a peak level at 7 to 9 h.
Therefore, H-FABP can be detected earlier in the circula-
tion after the onset of AMI. In contrast, TnT starts to
rise to greater than threshold values 3-6 h after the onset
of AMI and reaches a peak after 14 to 18 h. The sensitiv-
ity of TnT was expected to be low during the early phase
of chest pain, since cardiac troponin may not be detect-
able for up to 6 h after the onset of chest pain. The sensi-
tivity of Cardio Detect and TnT improved over time and
reached 100% in patients from group 3. The sensitivity of
Cardio Detect decreased after 24 h of chest pain (group
4). This is because the H-FABP level normalizes in the
circulation after 24 h, hence explaining the drop in
Table 2 Diagnostic indices of Cardio Detect and TnT
Parameter Cardio Detect
(95% CI)
TnT
(95% CI)
Sensitivity (%)
≤ 4 h 50.0 (20.1-79.8) 10.0 (0.5-45.9)
> 4 but ≤ 12 h 83.3 (42.0-99.2) 66.6 (30.2-94.8)
> 12 but ≤ 24 h 100.0 (46.2-100.0) 100.0 (46.3-100.0)
> 24 h 0.0 (0.0-94.5) 100.0 (5.4-100.0)
Specificity (%)
≤ 4 h 63.6 (40.8-81.9) 100.0 (81.5-100.0)
> 4 but ≤ 12 h 52.0 (33.7-72.8) 100.0 (83.9-100.0)
> 12 but ≤ 24 h 25.0 (3.9-59.8) 100.0 (62.8-100.0)
> 24 h 66.6 (12.5-98.2) 100.0 (30.9-100.0)
PPV (%)
≤ 4 h 38.4 (15.1-67.7) 100.0 (5.4-100.0)
> 4 but ≤ 12 h 29.4 (14.3-58.8) 100.0 (46.2-100.0)
> 12 but ≤ 24 h 45.5 (16.4-71.4) 100.0 (46.2-100.0)
> 24 h 0.0 (0.0-94.5) 100.0 (5.4-100.0)
NPV (%)
≤ 4 h 73.6 (48.5-89.8) 70.9 (51.7-85.1)
> 4 but ≤ 12 h 92.9 (66.0-99.6) 92.5 (75.0-98.7)
> 12 but ≤ 24 h 100.0 (19.7-100.0) 100.0 (62.8-100.0)
> 24 h 66.6 (12.5-98.2) 100.0 (30.9-100.0)
Figure 3 The ECG findings recorded at presentation to the ED.
Table 3 Diagnostic indices for repeat Cardio Detect and
combination tests
Parameter Repeat Cardio Detect
(95% CI)
Cardio Detect and TnT
(combination test)
Sensitivity (%)
≤ 4 h 60.0 (17.0-92.7) 60.0 (27.3-86.3)
> 4 but ≤ 12 h 50.0 (2.60-97.3) 100.0 (56.0-100.0)
> 12 but ≤ 24 h - 100.0 (46.2-100.0)
> 24 h - 100.0 (5.4-100.0)
Specificity (%)
≤ 4 h 85.7 (58.3-97.6) 63.6 (40.8-81.9)
> 4 but ≤ 12 h 50.0 (31.6-68.3) 52.0 (33.7-72.8)
> 12 but ≤ 24 h - 25.0 (3.9-59.8)
> 24 h - 66.6 (12.5-98.2)
PPV (%)
≤ 4 h 60.0 (17.0-92.7) 42.8 (18.8-70.3)
> 4 but ≤ 12 h 14.2 (0.3-32.2) 33.3 (17.2-61.3)
> 12 but ≤ 24 h - 45.5 (16.4-71.4)
> 24 h - 50.0 (2.6-97.3)
NPV (%)
≤ 4 h 85.7 (58.3-97.6) 77.7 (51.9-92.6)
> 4 but ≤ 12 h 85.7 (67.7-99.6) 100 (73.2-100.0)
> 12 but ≤ 24 h - 100.0 (19.7-100.0)
> 24 h - 100 (19.7-100)
Hisamuddin NAR and Suhailan M International Journal of Emergency Medicine 2011, 4:67
http://www.intjem.com/content/4/1/67
Page 6 of 9sensitivity. The ROC curve is a useful graphic method for
comparing different tests [32]. Comparison of the ROC
curves of Cardio Detect
® and TnT (Table 4) in patients
from group 1 showed that no test was apparently super-
ior to the other. The AUC for Cardio Detect was low
(0.568) but slightly larger than TnT (0.550) in group 1.
The P-values were not significant and the 95% CI
included 0.5, which suggest that both tests were uninfor-
mative during this time period. The AUC for Cardio
Detect
® remained lower than TnT in the remaining
groups, a finding that was not in keeping with previous
studies [33]. However, the AUC for Cardio Detect did
increase over time before declining after the 24-h period.
This could be explained by the release kinetics of circu-
lating H-FABP as previously discussed.
The rationale of performing these two tests simulta-
neously is to exploit the advantages of the two cardiac bio-
markers with different release kinetics. Combination of H-
FABP, which is released early, and a later marker such as
TnT may reduce the false-negative ratio and provide an
optimal diagnostic performance [34]. Alpert et al. also sug-
gested that different cardiac biomarkers, when performed
simultaneously on patients with chest pain in the ED, may
act synergistically and have a better diagnostic perfor-
mance when used in combination than when interpreted
individually.
This study demonstrated that the qualitative Cardio
Detect
® test, which detects H-FABP in the circulation,
was more sensitive than TnT and has a better NPV,
especially during the early hours of AMI. Cardio Detect
test may be potentially used to rule out myocardial
infarction during the early phase of ischemic chest pain.
However, there are still significant rates of false nega-
t i v e se v e ni nt h ee a r l yh o u r so fA M I ,a n df u r t h e r
improvement should be made to the Cardio Detect
®
test kit. This study also concluded that repeating the
Cardio Detect
® test 1 h after an initial negative result
improved the sensitivity, specificity, PPV, and NPV of
the test, especially during the first 4 h after the onset of
chest pain. The diagnostic accuracy of the repeat test
was also superior to the Cardio Detect
® test alone or
cardiac TnT during the early phase of chest pain. There-
fore, if the initial Cardio Detect
® test is negative, a
repeat test 1 h later is suggested, especially for patients
who present early after the onset of chest pain.
This study agreed with previous recommendations that
combination tests with different release kinetics (e.g.,
H-FABP and TnT) improved the diagnostic performance
of cardiac biomarkers in detecting AMI, as compared to
performing individual tests. It was shown that the combi-
nation test of Cardio Detect
® and TnT had a better diag-
nostic accuracy than an individual test, especially during
the first 4 h after AMI. The combination test, however,
m a yb er e d u n d a n ta sT n Tt e s ta l o n ew a sp r o v e nt ob e
adequately sensitive and specific in diagnosing AMI,
except for the early hours of chest pain. The Cardio
Detect
® test was more sensitive in detecting AMI during
the early hours of symptoms and has an added advantage
of having a better NPV compared to TnT [35-37]. These
characteristics of Cardio Detect
® are crucial since early
exclusion of AMI depends on the sensitivity and NPV.
A repeated Cardio Detect
® test an hour later is recom-
mended if the initial test is negative, as this was proven to
have better diagnostic indices. The combination test of
Cardio Detect and TnT may be beneficial in selected
patients, such as those who present with intermittent
chest pain and are unsure or unable to recall the exact
time of onset of chest pain. Combining the Cardio Detect
®
and TnT would provide a wide safety net to diagnose AMI
in these cases. With a high sensitivity and NPV, the com-
bination test may be beneficial in ruling out myocardial
infarction.
Limitations
Several limitations were found during the study:
1.T h eC a r d i oD e t e c t
® test kits were supplied in
batches. Half way through the study, an updated version
replaced the initial credit card-like test kit. The manu-
facturer reported that both test kits had similar charac-
teristics, including the same cutoff point for a positive
test to detect H-FABP. It is not known certainly whether
the initial and updated versions of the Cardio Detect
®
test kits were comparable in all aspects.
Table 4 Area under the ROC curves (AUC)
Test Area P-value 95% CI
≤ 4 h (group 1)
Cardio Detect (CardioD) 0.568 0.542 0.350-0.787
Troponin T (TropT) 0.550 0.655 0.325-0.775
Repeated CardioD 0.733 0.127 0.449-1.017
Combine CardioD & TropT 0.744 0.049 0.520-0.969
> 4 but ≤ 12 h (group 2)
CardioD 0.698 0.113 0.493-0.903
TropT 0.857 0.004 0.650-1.064
Repeated CardioD 0.500 1.000 -0.102 to 1.102
Combine CardioD & TropT 0.769 0.031 0.608-0.930
> 12 but ≤ 24 h (group 3)
CardioD 0.611 0.505 0.308-0.914
TropT 1.000 0.003 1.000-1.000
Combine CardioD & TropT 0.611 0.505 0.308-0.914
> 24 h (group 4)
CardioD 0.333 0.655 -0.283 to 0.949
TropT 1.000 0.180 1.000 - 1.000
Combine CardioD & TropT 0.833 0.371 0.384-1.282
*The closer the ROC curve comes to the 45-degree diagonal line of the ROC
space, the less accurate the test. An AUC of 1 represents a perfect test;
elsewhere an area of 0.5 represents an uninformative test.
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reading the Cardio Detect
® test result since they are not
blinded to the history, physical examination, and ECG
findings of the patient being investigated. Under ideal
experimental conditions, the Cardio Detect
® test would
have been read by a separate observer who is blinded to
the patient’s clinical condition. However, this was not
possible in a busy emergency department setting.
3. The subjective nature of the reports of the patients
about the exact onset of their ischemic symptoms may
potentially overestimate or underestimate the duration
of their ischemic symptoms. This may have influenced
the grouping of patients according to the predetermined
time frame and eventually affect the diagnostic indices
of the group studied.
4. Inter-observer variability between two observers
reading the Cardio Detect
® test was assessed in this
study. Care was taken to perform the Cardio Detect
® test
(and TnT) using standardized methods, and interpreta-
tion was done in a similar environment in the ED. The
Cardio Detect
® test kit result has a tendency to change
over time, and it was read at the 15-min mark. There
were instances when the second reader read the test
beyond 15 min. This delay may have contributed to the
different interpretation of the test and affected the kappa
analysis to assess agreement beyond chance between the
two readers.
Conclusion
The Cardio Detect
® test is more sensitive and has a better
NPV than troponin T during the first 12 h of AMI.
Repeating the Cardio Detect
® test 1 h after an initial nega-
tive result does improve the diagnostic indices, especially
during the first 4 h after the onset of chest pain. However,
those who present with intermittent chest pain and are
unsure or unable to recall the exact time of onset of chest
pain may benefit from the combination test.
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